.05.014EfficacyofInfraredHepatopathyTherapeuticInstrumentCombinedwithEentecavirandAnti-fibrosisDecoctioninthetreatmentofChronicHepatitisBinOlderPatientsShiNa1,SongJuanli2,WangJing1,YinYuhong3,ShangNing11HandanInfectiousDiseaseHospital,Handan056002,China23[Abstract]HandanCentralHospital,Handan056002,ChinaCommunityHealthServiceCenterofHepingStreet,CongtaiDistrict,Handan056002,ChinaObjectiveTostudytheefficacyofinfraredhepatopathytherapeuticinstrumentcombinedwithentecavirandanti-fibrosisdecoctioninthetreatmentofchronichepatitisBinolderpatients.Methods76olderpatientswithchronichepatitisBwereselectedfromAugust2015toAugust2016inHandanInfectiousDiseaseHospital.Thepatientsweredividedintothecontrolgroup(38cases)andtheexperimentalgroup(38cases)accordingtothetreatmentmethods.Thecontrolgroupwastreatedwithentecavirandanti-fibrosisdecoctionfor3months.Theexperimentalgroupwastreatedwithinfraredhepatopathytherapeuticinstrument,entecavirandanti-fibrosisdecoctionfor3months.Theliverfunctionindexes(ALT,AST,TBiL),liverfibrosisindexes(HA,LN,PC-Ⅲ,Ⅳ-C),HBeAg,HBV-DNA,thelevelsofinflammatoryfactors(IL-2,IL-6,IL-8,TNF-α,IL-1β,IFN-γ),andtheclinicalsymptomswerecomparedbetweenthetwogroups.ResultsAfter3monthsoftreatment,theimprovementofclinicalsymptomsintheexperimentalgroupwasbetterthanthatinthecontrolgroup(P0.05),具有可比后HBV-DNA水平低于300拷贝/ml为HBV-性。患者对本次研究完全知情,自愿签署知情同意DNA阴性,HBV-DNA转阴率=(治疗前-治疗书,符合伦理要求。后)HBV-DNA阳性例数/总例数×100%。⑥炎1.2症因子。ELASA检测白细胞介素2(interleukin-方法1.2.1对照组恩替卡韦及乙肝抗纤汤治疗3个2,IL-2)、IL-6、IL-8、IL-1β,肿瘤坏死因月。恩替卡韦分散片(国药准字H20100019,正大子α(tumornecrosisfactor-alpha,TNF-α)天晴药业集团股份有限公司生产,规格扰素γ(interferon-gamma,IFN-γ),试剂盒购0.5mg/片)口服,1片/次,1次/d;乙肝抗纤汤,1剂/d,分2次水煎服,该汤剂的药物组成为及干自上海生工生物工程有限公司。1.3统计学方法黄芪、太子参、冬虫夏草、鳖甲各30g,茯苓、白2应用SPSS19.0软件进行分析,计数资料行χ术、菟丝子、川芎、蜈蚣各15g,丹参20g,当检验,采用例(%)表示;计量资料行t检验,采用x珋±s表示。P0.05)。治疗3个月ALT(u/L)治疗前低于对照组(P0.05)。见表3。治疗3个月后,两组肝纤维化情况均得到有效改表3组别例数对照组两组治疗前后肝纤维化指标比较(x珋±s,ng/ml)HALNPC-ⅢⅣ-C38治疗前679.78±261.67417.83±188.31327.62±122.09335.29±177.11治疗后aaa260.22±106.29a422.63±173.72328.96±119.31338.91±109.28abab214.18±72.89ab实验组328.63±117.36365.15±107.62289.01±109.2838治疗前689.72±237.91治疗后218.77±108.32ab287.50±93.21238.19±82.29注:与治疗前比较aP

(聊城荣恒医疗器械有限公司)